News | November 16, 2025
ALBIS unveils next-gen healthcare materials at COMPAMED 2025
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
This collaboration turns kitting into a strategic advantage for sponsors and sites
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
Fenebrutinib targets cells in the immune system known as B cells and microglia
Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes
The high-performance polymer’s transparency and biocompatibility support precise implantation and long-term reliability
Subscribe To Our Newsletter & Stay Updated
